A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia

Kohei Hara, Akira Sakamoto, Kiyokazu Komori, Naomi Ito, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Masanari Mukai, Kazuo Takebe, Takeshi Osonoi, Yasuhisa Kuroda, Seijiro Abe, Masakichi Motomiya, Akira Watanabe, Kiyoshi Konno, Tsuueo Sayama, Kuniharu Shida, Satoshi Shinto, Satoshi Shoji, Hideo AraiTakeshi Kawai, Atsushi Saito, Osamu Sakai, Kohya Shiba, Masaki Yoshida, Kazuhisa Okada, Hiroichi Tanimoto, Kazuo Ohara, Tetsuo Okamura, Takashi Inamatsu, Yoshishige Masuda, Fumiko Oshima, Hiroyuki Kobayashi, Kohji Narui, Eiyasu Tsuboi, Tatsuo Nakatani, Yoshitaka Nakamori, Koichiro Nakata, Fumio Matsumoto, Takeo Imai, Iwao Sakurai, Takayuki Takahashi, Masayuki Morita, Masaaki Arakawa, Koichi Wada, Takashi Kawashima, Kenichi Igarashi, Hajimu Takeda, Masanaga Takato, Shigeyuki Hoshino, Nobuki Aoki, Atsuhiko Sato, Izumi Shichi, Teiji Tamura, Yutaka Nakano, Tamaki Matsubara, Masaaki Ida, Toshiyuki Yamamoto, Kanzo Suzuki, Satoru Adachi, Toshihiko Takeuchi, Yoshimitsu Hayashi, Kazuhide Yamamoto, Fumio Miki, Rinzo Soejima, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Kenji Hasegawa, Takafumi Tsuse, Osamu Kurimura, Kikuo Nakano, Masaaki Oune, Koji Takeda, Yoshiro Sawae, Ikuo Sumita, Takatoshi Inoue, Toshiyuki Ishimaru, Chiyuki Kawasaki, Kazuhiko Kato, Yoshiyuki Niho, Minoru Yoshida, Masayuki Nakanishi, Masanori Takayama, Kotaro Oizumi, Keizo Matsumoto, Masaru Nasu, Atsushi Saito, Yoshiteru Shigeno, Keizou Kitsukawa, Yuei Irabu, Hiroshi Fukuhara, Hiroshi Nakamura, Hajime Uema, Mitsuyoshi Nakashima, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

To evaluate the efficacy, safety and usefulness of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a multicenter double-blind controlled study was conducted using imipenem/cilastatin sodium (IPM/CS) as the reference drug. Patients were given 0.5 g of MEPM (the MEPM group) or 1.0 g/1.0 g of IPM/CS (the IPM/CS group) daily (b.i.d.) for 14 days as a rule. The results of evaluation by the committee were as follows: 1. Analyzed cases: Among a total of 146 cases, 113 cases were evaluated for clinical efficacy. These cases included 110 cases of bacterial pneumonia and 3 cases of lung abscess. 2. Clinical efficacy: In bacterial pneumonia, the efficacy rate was 87.5% (49/56) in the MEPM group vs. 92.6% (50/54) in the IPM/CS group. In all cases, the efficacy rate was 87.7% (50/57) in the MEPM group vs. 92.9% (52/56) in the IPM/CS group. There were no significant differences between the two groups. 3. Bacteriological response: The eradication rate was 95.8% (23/24) in the MEPM group vs. 93.1% (27/29) in the IPM/CS group. There was no significant difference between the two groups. 4. Safety: As side effects, nausea and diarrhea were noticed in 1 of 72 patients in the IPM/CS group. The incidence of abnormal laboratory findings was 36.4% (24/66) in the MEPM group vs. 27.8% (20/72) in the IPM/CS group. There was no significant difference between the two groups. Chief abnormalities were an increase in eosinophils and transient elevations of GOT and GPT. 5. Usefulness: In bacterial pneumonia the usefulness rate was 85.7% (48/56) in the MEPM group vs. 90.9% (50/55) in the IPM/CS group. In all cases the rate was 86.0% (49/57) in the MEPM group vs. 91.2% (52/57) in the IPM/CS group. There were no significant differences between the two groups. From the above results we concluded that 0.5 g/day of MEPM was as useful as 1.0 g/1.0 g/day of IPM/CS in bacterial pneumonia.

Original languageEnglish
Pages (from-to)1343-1364
Number of pages22
JournalChemotherapy
Volume40
Issue number11
DOIs
Publication statusPublished - 1992 Nov

Keywords

  • Meropenem
  • imipenem/cilastatin sodium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia'. Together they form a unique fingerprint.

Cite this